2024-01-10 07:35:55 ET
- Rapid Micro Biosystems ( NASDAQ: RPID ) expects Q4 total revenue of $6.2M and $6.4M, representing growth of approximately 45% compared to the prior-year period.
- FY23 total revenue is anticipated in the range of $22.4M and $22.6M vs $22.41M consensus.
- The Company placed 16 new systems with customers and completed the validation of 18 new customer systems during 2023. The company ended 2023 with approx. $95M in cash and investments.
- The Company plans to announce Q4 results in March.
- The Company is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 12:45 p.m. ET.
- In another event, the company expects the commercial launch of the growth direct rapid sterility application by mid-year 2024 .
- Source: Press Release
For further details see:
Rapid Micro Biosystems issues Q4 and FY23 guidance